Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States (Genital HPV infection, CDC).
There are more than 200 different types of HPV, around 40 types of HPV that affect the genital area, and 14 clinically relevant high-risk HPV genotypes. The different types of HPV are given numbers and known as HPV genotypes.
Someone who develops an HPV infection can go years without having any symptoms. Most of the time HPV goes away on its own, other times it can cause genital warts, precancer or cancer.
There are differences not only in the prevalence of the HPV genotypes, but also in the risk of those genotypes to cause cervical cancer.
Almost all cervical cancer can be prevented by HPV vaccination, but vaccination isn’t enough because the vaccine coverage is about half of the young population.
There are two different types of HPV vaccines in the US.
There are three common cervical cancer screening paradigms in the US.
A variety of HPV tests can be used to detect HPV genotypes and determine a woman's risk of developing cervical precancer and cancer.
Persistence of HPV, with one of the hr-HPV genotypes, is necessary for the development of cervical precancer and cancer.
A positive HPV test requires further investigation, and the 2019 American Society for Colposcopy and Cervical Pathology (ASCCP) cervical cancer management guidelines recommend a personalized risk-based management.
As the vaccinated population increases, HPV 16 and 18 are decreasing in prevalence, making it crucial to identify the other high-risk HPV genotypes.
Extended genotyping allows for a more precise way to measure your patient’s risk for developing cervical precancer and cancer vs. a pooled, high-risk assay.
There are currently 5 FDA-approved HPV assays – each has a different number of results, based on the different hr-HPV genotypes detected and whether these genotypes are reported as a grouped result or as an individual result.
Only an HPV assay with extended genotyping can individually identify hr-HPV genotypes beyond HPV 16 and 18, including HPV 31, which poses a similar risk for cervical precancer as compared to HPV 18 and should be managed similarly.
Genotype-specific HPV persistence is the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotype.
Extended genotyping provides specific, actionable insights on an extended set of HPV genotypes.
Shape the future of cervical cancer screening with the BD Onclarity™ HPV Assay.
Following the American Society for Colposcopy and Cervical Pathology (ASCCP) principle of “similar management for similar risk”, women with an immediate risk for CIN3+ disease above 4% should be referred to colposcopy.
Multiple studies conclude that genotype-specific hr-HPV persistence is the most important determinant of cervical cancer risk in women who test HPV-positive, regardless of HPV genotype.
The BD Onclarity™ HPV Assay is designed to reduce the risk of false-positive results due to lack of cross-reactivity with low-risk HPV types
The BD Onclarity™ HPV Assay is FDA-approved for the three most common paradigms and also for extended genotyping, offering the flexibility you need to adapt to changing screening guidelines.
An overview of all FDA-approved HPV assays
The BD Onclarity™ HPV Assay was extensively tested among women of different ages, ethnicities, and vaccination status in a prospective, multicenter clinical trial that enrolled more than 33,000 women.
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), and Trichomonas vaginalis (TV) are the most prevalent non-viral causes of sexually transmitted infections and accounted for ~$1.1 billion in direct medical costs in 2018.
Chlamydia – caused by infection with Chlamydia trachomatis (CT) bacterium – is the most frequently reported bacterial sexually transmitted infection in the United States.
Gonorrhea – caused by infection with Neisseria gonorrhoeae (GC) bacterium – is the second most commonly reported bacterial sexually transmitted infection in the United States.
Trichomoniasis - caused by infection with the parasite Trichomonas vaginalis - is the most prevalent non-viral STI worldwide.
STIs are on the rise and remain a significant public health concern.
Following STI testing guidelines may help identify asymptomatic cases of infection and protect them from the consequences of STIs.
The BD CTGCTV2 assay is a 3-in-1 FDA-cleared test designed to detect the 3 most prevalent non-viral sexually transmitted infections simultaneously and separately.
The BD CTGCTV2 assay can be run on patient- and clinician-collected vaginal swabs*, urine samples, endocervical swabs**, and on liquid-based cytology media (PreservCyt)**, with similar performance.
Vaginitis and STI co-infection is common. Identify it from visit 1, with one swab.
Learn more about our BD Women’s Health solutions
